WO2000064460A3 - Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin - Google Patents

Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin Download PDF

Info

Publication number
WO2000064460A3
WO2000064460A3 PCT/IB2000/000480 IB0000480W WO0064460A3 WO 2000064460 A3 WO2000064460 A3 WO 2000064460A3 IB 0000480 W IB0000480 W IB 0000480W WO 0064460 A3 WO0064460 A3 WO 0064460A3
Authority
WO
WIPO (PCT)
Prior art keywords
recovery
mixture
natural protein
bone
irreversible
Prior art date
Application number
PCT/IB2000/000480
Other languages
French (fr)
Other versions
WO2000064460A2 (en
Inventor
Diego Braguglia
Pedro Bittmann
Sophie Feldblum
Sonia Arnaud
Original Assignee
Sulzer Orthopedics Ltd
Diego Braguglia
Pedro Bittmann
Sophie Feldblum
Sonia Arnaud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulzer Orthopedics Ltd, Diego Braguglia, Pedro Bittmann, Sophie Feldblum, Sonia Arnaud filed Critical Sulzer Orthopedics Ltd
Priority to AU36671/00A priority Critical patent/AU3667100A/en
Publication of WO2000064460A2 publication Critical patent/WO2000064460A2/en
Publication of WO2000064460A3 publication Critical patent/WO2000064460A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin and including cerebral ischemia and stroke is enhanced by administration of a composition comprising a therapeutically effective amount of a natural protein mixture derived from bone, cartilage and/or tendon/ligament tissue and having bone morphogenic and/or osteoinductive characteristics. This natural protein mixture is preferably the mixture known as BP (Bome Protein) which mixture is derived from bovine bone material by extracting proteins from demineralized bone particles and purifying the extract by ultrafiltration, anion exchange, cation exchange and reverse phase high resolution liquid chromatography. In the rat model it is shown that the enhancement regarding BP-treated animals compared with sham-treated animals includes acceleration of recovery for reversible and irreversible cases of spinal cord lesions and a higher recovery level, i.e. a smaller irreversible functional loss for irreversible cases. Recovery is believed to be due to the beneficial effect of the natural protein mixture on cell survival after injury, on cell protection against exitotoxicity (e.g. glutamate intoxication) as well as on injury site conditions favoring axon regeneration. Compared with known administration of single species of recombinantly produced bone morphogenic proteins for similar aims, the natural protein mixture is effective in considerably lower doses.
PCT/IB2000/000480 1999-04-23 2000-04-19 Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin WO2000064460A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU36671/00A AU3667100A (en) 1999-04-23 2000-04-19 Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13074199P 1999-04-23 1999-04-23
US60/130,741 1999-04-23

Publications (2)

Publication Number Publication Date
WO2000064460A2 WO2000064460A2 (en) 2000-11-02
WO2000064460A3 true WO2000064460A3 (en) 2001-02-08

Family

ID=22446103

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/000480 WO2000064460A2 (en) 1999-04-23 2000-04-19 Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin

Country Status (2)

Country Link
AU (1) AU3667100A (en)
WO (1) WO2000064460A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0400005A3 (en) * 2001-05-17 2012-09-28 Serono Lab Use of osteopontin for the treatment and/or prevention of neurologic diseases
FI117667B (en) 2001-07-05 2007-01-15 Univ Zuerich A pharmaceutical composition suitable for use in orthopedics and dentistry
GB0207829D0 (en) * 2002-04-04 2002-05-15 Isis Innovations Ltd Stimulation of nerve cell regeneration

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015323A1 (en) * 1991-03-11 1992-09-17 Creative Biomolecules, Inc. Protein-induced morphogenesis
US5290763A (en) * 1991-04-22 1994-03-01 Intermedics Orthopedics/Denver, Inc. Osteoinductive protein mixtures and purification processes
WO1994005791A2 (en) * 1992-09-03 1994-03-17 Regeneron Pharmaceuticals, Inc. Dorsal tissue affecting factor and compositions
US5756457A (en) * 1993-08-26 1998-05-26 Genetics Institute, Inc. Neural regeneration using human bone morphogenetic proteins
WO1999015191A2 (en) * 1997-09-19 1999-04-01 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Cytokines having neurotrophic activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015323A1 (en) * 1991-03-11 1992-09-17 Creative Biomolecules, Inc. Protein-induced morphogenesis
US5290763A (en) * 1991-04-22 1994-03-01 Intermedics Orthopedics/Denver, Inc. Osteoinductive protein mixtures and purification processes
WO1994005791A2 (en) * 1992-09-03 1994-03-17 Regeneron Pharmaceuticals, Inc. Dorsal tissue affecting factor and compositions
US5756457A (en) * 1993-08-26 1998-05-26 Genetics Institute, Inc. Neural regeneration using human bone morphogenetic proteins
WO1999015191A2 (en) * 1997-09-19 1999-04-01 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Cytokines having neurotrophic activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FELDBLUM S ET AL: "New cocktail of bone morphogenic proteins promotes functional motor recovery in a model of traumatic spinal cord injury.", SOCIETY FOR NEUROSCIENCE ABSTRACTS., vol. 25, no. 1-2, 1999, 29th Annual Meeting of the Society for Neuroscience.;Miami Beach, Florida, USA; October 23-28, 1999, pages 1334, XP000953009, ISSN: 0190-5295 *
LEVINE J P ET AL: "Bone morphogenetic protein promotes vascularization and osteoinduction in preformed hydroxyapatite in the rabbit", ANNALS OF PLASTIC SURGERY,US,LITTLE, BROWN AND CO, vol. 39, no. 2, August 1997 (1997-08-01), pages 158 - 168, XP002115397, ISSN: 0148-7043 *
PERIDES G ET AL: "NEUROPROTECTIVE EFFECT OF HUMAN OSTEOGENIC PROTEIN-1 IN A RAT MODEL OF CEREBRAL HYPOXIA/ISCHEMIA", NEUROSCIENCE LETTERS,IE,LIMERICK, vol. 187, 1995, pages 21 - 24, XP002037656, ISSN: 0304-3940 *

Also Published As

Publication number Publication date
WO2000064460A2 (en) 2000-11-02
AU3667100A (en) 2000-11-10

Similar Documents

Publication Publication Date Title
Wolfgram et al. THE COMPOSITION OF THE MYELIN PROTEINS OF THE CENTRAL NERVOUS SYSTEM 1 2
Urist et al. Purification of bovine bone morphogenetic protein by hydroxyapatite chromatography.
Jung et al. Preparation of hoki (Johnius belengerii) bone oligophosphopeptide with a high affinity to calcium by carnivorous intestine crude proteinase
CA2107481C (en) Osteoinductive protein mixtures and purification processes
JP2010513513A5 (en)
EP2514445A3 (en) Bioactive hydrogel compositions
EP1420031A3 (en) Bone morphogenetic protein (BMP)-18 compositions
KR880004084A (en) Lipase and Lipase Extracts, Their Preparation and Therapeutic Uses
JPH0873324A (en) Hair-tonic and hair-growing agent
Tuross Albumin preservation in the Taima-taima mastodon skeleton
Fujii et al. Isolation of skeletal muscle collagen
WO2000064460A3 (en) Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin
US4216204A (en) Medical protein hydrolysate, process of making the same and processes of utilizing the protein hydrolysate to aid in healing traumatized areas
RU2011121684A (en) PROTEIN-polypeptide complex (LTP) has a tissue specific regenerative-reparative and anti-aging effect on skin tissue, METHOD FOR PRODUCING PROTEIN-polypeptide complex having a tissue specific regenerative-reparative and anti-aging effect on skin tissue, and pharmaceutical compositions having tissue specific regenerative-reparative action on LEATHER TISSUE, FOR MEDICINES FOR THE TREATMENT OF AUTOIMMUNE, VASCULAR, TRAUMATIC, TOXIC SKIN DISEASES, Also in aesthetic medicine and cosmetology
UA46764C2 (en) BIOACTIVE CONCENTRATE, METHOD OF ITS PREPARATION AND MEDICINAL COMPOSITIONS CONTAINING THIS CONCENTRATE
RU2001116296A (en) The method of obtaining soy protein product
Korneluk et al. Stage dependency of forelimb regeneration on nerves in postmetamorphic froglets of Xenopus laevis
ES2367523T3 (en) COSMETIC COMPOSITION CONTAINING CYNARA CARDUNCULUS OR SILYBUM MARIANUM OILS.
Brunish et al. Composition of histone prepared from rat liver deoxypentosenucleoprotein
Rikkers et al. Vitamin D binding globulin in the rat: Specificity for the vitamins D
US20120071414A1 (en) Method for producing and using active principles of limestone
Tator et al. Effect of triiodo-L-thyronine on axonal regeneration in the rat spinal cord after acute compression injury
Nagata et al. Effect of degeneration of sympathetic ganglion cells on amino acid metabolism in cervical ganglion from the rat
WO2004071524A1 (en) Albumin solution and method for the production thereof
Darlington et al. Comparison of the effects of ACTH-(4–10) on medial vestibular nucleus neurons in brainstem slices from labyrinthine-intact and compensated guinea pigs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP